SecBot SecBot

URGN

UroGen Pharma Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001668243 Biotech & Drug Discovery
$28.10 +1.92 (+7.33%)
Nov 16 4:00 PM ET · prev $26.18
Market cap
$1.3B
Small cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$60.00
+114% · range $54.00–75.00
1 year
+18.6%
from $23.70 · Nov 17
30 days
−17.7%
from $34.15
52-week range
$17.00–50.29
−44% from high · low Mar 30
Avg volume 20D
1.40M
Nov 16 spike 3.98M
Short interest
5.11M
≈10.4% of shares · −8.9%
Days to cover
5.1
at average volume
Insider net
−$4.5M
0 buyers · 3 sellers · 12 mo
New fund stakes
4
Q3 2026 13F · 3 exits
Filing reports
12
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 1 bearish · 1 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 7/9 ·Next FDA decision date, Jun 14, 2027

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $4.5M.

  • InstitutionsBULLISH

    Q3 2026: 33 added (4 new), 11 trimmed or exited. Largest new: Ing Groep Nv $91.7M, Walleye Capital $14.1M.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate $0.390 → $0.448 over 90 days. 5 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −8.9% to 5.11M shares. 5.1 days to cover, ≈10.4% of shares.

  • TrendDOWNTREND

    23% below its 50-day average.

Who's buying

13F· Q3 2026
4
new positions
3
exits
$117.5M
in new stakes · top 3 shown
FundMoveSharesValue
ING GROEP NVNEW180,000$91.7M
Walleye Capital LLCNEW348,116$14.1M
FEDERATED HERMES, INC.DOUBLED305,217$12.4M
Qube Research & Technologies LtdNEW287,222$11.7M
UBS Group AGDOUBLED266,218$10.8M
Nuveen, LLCDOUBLED240,822$9.8M
JPMORGAN CHASE & CODOUBLED210,356$8.5M
Russell Investments Group, Ltd.ADD183,076$7.4M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy6Buy6Hold1Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +114%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Oct 19, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 6, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 5, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Jul 21, 2026Guggenheim
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$4.5M
sold · 3 insiders
DateInsiderTypeValue
Oct 8, 2026
Degnan Chris
Chief Financial Officer
Oct 8, 2026
EXERCISE4,483 sh
Oct 8, 2026
Degnan Chris
Chief Financial Officer
Oct 8, 2026
SELL$80.8K
Sep 8, 2026
Smith Jason Drew
General Counsel
Sep 8, 2026
SELL$64.6K
Sep 8, 2026
Schoenberg Mark
Chief Medical Officer
Sep 8, 2026
SELL$37.4K
Sep 7, 2026
Smith Jason Drew
General Counsel
Sep 7, 2026
EXERCISE3,334 sh
Sep 7, 2026
Schoenberg Mark
Chief Medical Officer
Sep 7, 2026
EXERCISE1,667 sh
Aug 26, 2026
Robinson James A. Jr.
Director
Aug 26, 2026
EXERCISE2,000 sh
Aug 20, 2026
Schoenberg Mark
Chief Medical Officer
Aug 20, 2026
SELL$2.9M

Earnings setup

Estimates
$0.45
EPS estimate, this quarter
+15%
estimate change, 90 days
5↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.45$0.13–$0.66+15.0%$107.1M
Next Q$0.32$0.01–$0.68-23.6%$114.5M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

8 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
5,107,819
shares short
-8.9%
vs prior settlement
5.1
days to cover
≈10.4%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent

SecBot reports

12 filings · 4 press releases · 2 bullish · 1 bearish · 9 neutral
All URGN filing & press-release reports (16)